Trial Profile
A Multinational, Randomized, Double-Blind Study of Aflibercept Versus Placebo With Irinotecan/ 5-FU Combination (FOLFIRI) in Patients With Metastatic Colorectal Cancer (MCRC) After Failure of an Oxaliplatin Based Regimen
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Oct 2016
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms AFLAME
- Sponsors Sanofi
- 25 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 09 Jul 2015 Planned End Date changed from 1 Oct 2015 to 1 Jul 2015 as per ClinicalTrials.gov record.
- 14 Oct 2014 Status changed from recruiting to active, no longer recruiting, as reported by the ClinicalTrials.gov record.